This HTML5 document contains 223 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/pharmgkb/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/wikipedia/
n15http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n30http://linked.opendata.cz/resource/drugbank/mixture/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/kegg-compound/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/pubchem-compound/
n16http://www.drugs.com/
n22http://bio2rdf.org/drugbank:
n28http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/pubchem-substance/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n8http://www.rxlist.com/cgi/generic/
n31http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/national-drug-code-directory/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB00635/identifier/chebi/
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00635
rdf:type
n3:Drug
n3:description
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]
n3:dosage
n14:271B5D82-363D-11E5-9242-09173F13E4C5 n14:271B5D83-363D-11E5-9242-09173F13E4C5 n14:271B5D84-363D-11E5-9242-09173F13E4C5 n14:271B5D85-363D-11E5-9242-09173F13E4C5 n14:271B5D86-363D-11E5-9242-09173F13E4C5 n14:271B5D87-363D-11E5-9242-09173F13E4C5 n14:271B5D88-363D-11E5-9242-09173F13E4C5 n14:271B5D89-363D-11E5-9242-09173F13E4C5 n14:271B5D8A-363D-11E5-9242-09173F13E4C5 n14:271B5D8B-363D-11E5-9242-09173F13E4C5 n14:271B5D8C-363D-11E5-9242-09173F13E4C5 n14:271B5D8D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# FDA label
n3:group
approved
n3:halfLife
Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.
n3:indication
For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
n3:manufacturer
n4:271B5D64-363D-11E5-9242-09173F13E4C5 n4:271B5D65-363D-11E5-9242-09173F13E4C5 n4:271B5D40-363D-11E5-9242-09173F13E4C5 n4:271B5D57-363D-11E5-9242-09173F13E4C5 n4:271B5D58-363D-11E5-9242-09173F13E4C5 n4:271B5D55-363D-11E5-9242-09173F13E4C5 n4:271B5D56-363D-11E5-9242-09173F13E4C5 n4:271B5D53-363D-11E5-9242-09173F13E4C5 n4:271B5D54-363D-11E5-9242-09173F13E4C5 n4:271B5D51-363D-11E5-9242-09173F13E4C5 n4:271B5D52-363D-11E5-9242-09173F13E4C5 n4:271B5D5F-363D-11E5-9242-09173F13E4C5 n4:271B5D60-363D-11E5-9242-09173F13E4C5 n4:271B5D5D-363D-11E5-9242-09173F13E4C5 n4:271B5D5E-363D-11E5-9242-09173F13E4C5 n4:271B5D5B-363D-11E5-9242-09173F13E4C5 n4:271B5D5C-363D-11E5-9242-09173F13E4C5 n4:271B5D59-363D-11E5-9242-09173F13E4C5 n4:271B5D5A-363D-11E5-9242-09173F13E4C5 n4:271B5D47-363D-11E5-9242-09173F13E4C5 n4:271B5D48-363D-11E5-9242-09173F13E4C5 n4:271B5D45-363D-11E5-9242-09173F13E4C5 n4:271B5D46-363D-11E5-9242-09173F13E4C5 n4:271B5D43-363D-11E5-9242-09173F13E4C5 n4:271B5D44-363D-11E5-9242-09173F13E4C5 n4:271B5D41-363D-11E5-9242-09173F13E4C5 n4:271B5D42-363D-11E5-9242-09173F13E4C5 n4:271B5D4F-363D-11E5-9242-09173F13E4C5 n4:271B5D50-363D-11E5-9242-09173F13E4C5 n4:271B5D4D-363D-11E5-9242-09173F13E4C5 n4:271B5D4E-363D-11E5-9242-09173F13E4C5 n4:271B5D4B-363D-11E5-9242-09173F13E4C5 n4:271B5D4C-363D-11E5-9242-09173F13E4C5 n4:271B5D49-363D-11E5-9242-09173F13E4C5 n4:271B5D4A-363D-11E5-9242-09173F13E4C5 n4:271B5D70-363D-11E5-9242-09173F13E4C5 n4:271B5D71-363D-11E5-9242-09173F13E4C5 n4:271B5D6E-363D-11E5-9242-09173F13E4C5 n4:271B5D6F-363D-11E5-9242-09173F13E4C5 n4:271B5D6C-363D-11E5-9242-09173F13E4C5 n4:271B5D6D-363D-11E5-9242-09173F13E4C5 n4:271B5D6A-363D-11E5-9242-09173F13E4C5 n4:271B5D6B-363D-11E5-9242-09173F13E4C5 n4:271B5D63-363D-11E5-9242-09173F13E4C5 n4:271B5D61-363D-11E5-9242-09173F13E4C5 n4:271B5D72-363D-11E5-9242-09173F13E4C5 n4:271B5D62-363D-11E5-9242-09173F13E4C5 n4:271B5D68-363D-11E5-9242-09173F13E4C5 n4:271B5D69-363D-11E5-9242-09173F13E4C5 n4:271B5D66-363D-11E5-9242-09173F13E4C5 n4:271B5D67-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00635 n22:DB00635
dcterms:title
Prednisone
adms:identifier
n19:46508166 n20:PA451100 n21:5865 n23:C07370 n24:0054-8739-25 n25:DB00635 n26:8382 n27:5656 n28:D00473 n29:Prednisone
n3:mechanismOfAction
Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
n3:packager
n4:271B5D06-363D-11E5-9242-09173F13E4C5 n4:271B5D07-363D-11E5-9242-09173F13E4C5 n4:271B5D04-363D-11E5-9242-09173F13E4C5 n4:271B5D05-363D-11E5-9242-09173F13E4C5 n4:271B5CFF-363D-11E5-9242-09173F13E4C5 n4:271B5D12-363D-11E5-9242-09173F13E4C5 n4:271B5D13-363D-11E5-9242-09173F13E4C5 n4:271B5D10-363D-11E5-9242-09173F13E4C5 n4:271B5D11-363D-11E5-9242-09173F13E4C5 n4:271B5D16-363D-11E5-9242-09173F13E4C5 n4:271B5D17-363D-11E5-9242-09173F13E4C5 n4:271B5D14-363D-11E5-9242-09173F13E4C5 n4:271B5D15-363D-11E5-9242-09173F13E4C5 n4:271B5D0A-363D-11E5-9242-09173F13E4C5 n4:271B5D0B-363D-11E5-9242-09173F13E4C5 n4:271B5D08-363D-11E5-9242-09173F13E4C5 n4:271B5D09-363D-11E5-9242-09173F13E4C5 n4:271B5D0E-363D-11E5-9242-09173F13E4C5 n4:271B5D0F-363D-11E5-9242-09173F13E4C5 n4:271B5D0C-363D-11E5-9242-09173F13E4C5 n4:271B5D0D-363D-11E5-9242-09173F13E4C5 n4:271B5D36-363D-11E5-9242-09173F13E4C5 n4:271B5D37-363D-11E5-9242-09173F13E4C5 n4:271B5D24-363D-11E5-9242-09173F13E4C5 n4:271B5D25-363D-11E5-9242-09173F13E4C5 n4:271B5D22-363D-11E5-9242-09173F13E4C5 n4:271B5D23-363D-11E5-9242-09173F13E4C5 n4:271B5D30-363D-11E5-9242-09173F13E4C5 n4:271B5D31-363D-11E5-9242-09173F13E4C5 n4:271B5D2E-363D-11E5-9242-09173F13E4C5 n4:271B5D2F-363D-11E5-9242-09173F13E4C5 n4:271B5D34-363D-11E5-9242-09173F13E4C5 n4:271B5D35-363D-11E5-9242-09173F13E4C5 n4:271B5D32-363D-11E5-9242-09173F13E4C5 n4:271B5D33-363D-11E5-9242-09173F13E4C5 n4:271B5D28-363D-11E5-9242-09173F13E4C5 n4:271B5D29-363D-11E5-9242-09173F13E4C5 n4:271B5D26-363D-11E5-9242-09173F13E4C5 n4:271B5D27-363D-11E5-9242-09173F13E4C5 n4:271B5D2C-363D-11E5-9242-09173F13E4C5 n4:271B5D2D-363D-11E5-9242-09173F13E4C5 n4:271B5D2A-363D-11E5-9242-09173F13E4C5 n4:271B5D2B-363D-11E5-9242-09173F13E4C5 n4:271B5D20-363D-11E5-9242-09173F13E4C5 n4:271B5D21-363D-11E5-9242-09173F13E4C5 n4:271B5D1A-363D-11E5-9242-09173F13E4C5 n4:271B5D1B-363D-11E5-9242-09173F13E4C5 n4:271B5D18-363D-11E5-9242-09173F13E4C5 n4:271B5D19-363D-11E5-9242-09173F13E4C5 n4:271B5D1E-363D-11E5-9242-09173F13E4C5 n4:271B5D3B-363D-11E5-9242-09173F13E4C5 n4:271B5D1F-363D-11E5-9242-09173F13E4C5 n4:271B5D3C-363D-11E5-9242-09173F13E4C5 n4:271B5D1C-363D-11E5-9242-09173F13E4C5 n4:271B5D39-363D-11E5-9242-09173F13E4C5 n4:271B5D1D-363D-11E5-9242-09173F13E4C5 n4:271B5D3A-363D-11E5-9242-09173F13E4C5 n4:271B5D3F-363D-11E5-9242-09173F13E4C5 n4:271B5D3D-363D-11E5-9242-09173F13E4C5 n4:271B5D3E-363D-11E5-9242-09173F13E4C5 n4:271B5D38-363D-11E5-9242-09173F13E4C5 n4:271B5D02-363D-11E5-9242-09173F13E4C5 n4:271B5D03-363D-11E5-9242-09173F13E4C5 n4:271B5D00-363D-11E5-9242-09173F13E4C5 n4:271B5D01-363D-11E5-9242-09173F13E4C5
n3:patent
n31:6488960 n31:6677326 n31:8309124 n31:8394407
n3:routeOfElimination
Excreted in the urine as sulfate and glucuronide conjugates.
n3:synonym
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione 1,2-Dehydrocortisone Prednisonum 1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione Dehydrocortisone Prednisona
n10:hasAHFSCode
n15:68-04-00
n3:foodInteraction
Take with food to reduce irritation. Avoid alcohol. When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state. Avoid taking with grapefruit juice.
n3:mixture
n30:271B5CFB-363D-11E5-9242-09173F13E4C5 n30:271B5CFC-363D-11E5-9242-09173F13E4C5 n30:271B5CFD-363D-11E5-9242-09173F13E4C5 n30:271B5CFE-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Extensively bound to plasma proteins.
n3:synthesisReference
Jean Buendia, Michel Vivat, "Process for the production of prednisone 17.21-diacylates." U.S. Patent US4601854, issued May, 1982.
n12:hasConcept
n13:M0017465
foaf:page
n8:pred.htm n16:prednisone.html
n3:IUPAC-Name
n9:271B5D92-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B5D98-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B5D97-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B5D94-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B5D95-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B5D96-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B5D90-363D-11E5-9242-09173F13E4C5 n9:271B5DA8-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B5D8E-363D-11E5-9242-09173F13E4C5 n9:271B5D91-363D-11E5-9242-09173F13E4C5 n9:271B5DAA-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B5D8F-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:A07EA03 n11:H02AB07
n3:H-Bond-Acceptor-Count
n9:271B5D9E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B5D9F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B5D99-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B5D9A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B5D9C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B5D9B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B5D9D-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
53-03-2
n3:category
n3:containedIn
n17:271B5D7C-363D-11E5-9242-09173F13E4C5 n17:271B5D7D-363D-11E5-9242-09173F13E4C5 n17:271B5D7A-363D-11E5-9242-09173F13E4C5 n17:271B5D7B-363D-11E5-9242-09173F13E4C5 n17:271B5D80-363D-11E5-9242-09173F13E4C5 n17:271B5D81-363D-11E5-9242-09173F13E4C5 n17:271B5D7E-363D-11E5-9242-09173F13E4C5 n17:271B5D7F-363D-11E5-9242-09173F13E4C5 n17:271B5D74-363D-11E5-9242-09173F13E4C5 n17:271B5D75-363D-11E5-9242-09173F13E4C5 n17:271B5D73-363D-11E5-9242-09173F13E4C5 n17:271B5D78-363D-11E5-9242-09173F13E4C5 n17:271B5D79-363D-11E5-9242-09173F13E4C5 n17:271B5D76-363D-11E5-9242-09173F13E4C5 n17:271B5D77-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B5DA4-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B5DA6-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B5DA7-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B5DA9-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B5DA3-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B5DA2-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B5DA5-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B5D93-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B5DA0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B5DA1-363D-11E5-9242-09173F13E4C5